LUMIFY Drug Patent Profile

When do Lumify patents expire, and what generic alternatives are available?

Lumify is a drug marketed by Bausch And Lomb Inc and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumify

A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB INC on May 28^th, 2003.

Summary for LUMIFY

International Patents:	37
US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	8
Patent Applications:	130
Drug Prices:	Drug price information for LUMIFY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIFY
DailyMed Link:	LUMIFY at DailyMed

See drug prices for LUMIFY

Recent Clinical Trials for LUMIFY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tulane University	Phase 4
Bausch & Lomb Incorporated	PHASE3
University of Louisville	Phase 4

See all LUMIFY clinical trials

Pharmacology for LUMIFY

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for LUMIFY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUMIFY	Ophthalmic Solution	brimonidine tartrate	0.025%	208144	1	2021-07-12

US Patents and Regulatory Information for LUMIFY

LUMIFY is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes

International Patents for LUMIFY

See the table below for patents covering LUMIFY around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112016004054
Canada	2732521
Canada	2782817
Canada	2832953
Canada	2865593
Cyprus	1115727

Supplementary Protection Certificates for LUMIFY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221

Last updated: July 28, 2026

LUMIFY (l is? LUMIFY) market dynamics and financial trajectory (2026 outlook)

LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) remains a niche, category-defining over-the-counter (OTC) and prescription-adjacent dry-eye/conjunctival hyperemia product with steady demand driven by repeatable use, pharmacy shelf availability, and a patent-lite competitive field. Financial performance is constrained by the small, seasonal, and substitution-heavy use case (temporary redness relief), not by blockbuster-style chronic indications. Post-launch growth is largely tied to channel expansion (retail pharmacy and e-commerce) and to sustaining pricing power against generics and private label where authorized.

---

How is LUMIFY priced and what drives market demand for brimonidine 0.025% eye drops?

What is the product’s commercial positioning

• Active ingredient: brimonidine tartrate
• Strength/form: ophthalmic solution 0.025%
• Clinical use in commerce: temporary relief of redness due to minor eye irritation and other external causes (conjunctival hyperemia), typically for short-duration symptomatic use.

Key demand drivers

1. Repeat purchase behavior
   • Redness relief is episodic, creating frequent reordering when users keep a bottle at home or travel.
2. OTC distribution economics
   • LUMIFY’s shelf access at retail pharmacy is a primary driver of conversion because the use case is self-directed.
3. Seasonality
   • Demand typically rises with high-irritant periods (allergy season, travel, indoor/dry conditions), though overall category size remains capped.
4. Substitution and multi-brand competition
   • Eye redness relief competes with alternative OTC “redness drops” (different mechanisms, different actives), so incremental volume is sensitive to relative price and perceived effect speed/duration.

What suppresses demand growth

• No durable prevention or chronic disease claim
  • Commercial messaging centers on symptomatic relief, limiting sustained daily use and payer-driven uptake.
• High switching propensity
  • OTC category consumers often trial and switch across brands if price-performance is comparable.

---

How big is the addressable market and what share does LUMIFY typically win in eye redness relief?

Market structure

• The “eye redness relief” market splits into:
  • Brimonidine-based OTC options
  • Vasoconstrictor-based drops (mechanism competition)
  • Allergy adjunct products (users may pivot based on perceived cause)
  • Private label and generic equivalents where available

Share determinants

• Branded consumer recognition
  • Brand recall matters because purchase decisions are immediate and time-constrained.
• Retail execution
  • Planogram placement and promotional intensity move unit sales.
• Perceived efficacy and tolerability
  • Users compare speed of symptom reduction and sting/burning profile across competing actives.

Financial implication

• LUMIFY’s share is not constrained only by marketing spend. It is limited by how quickly a consumer returns to baseline and how often they decide to keep buying the same SKU versus trying competitors.

---

What financial trajectory has LUMIFY shown since launch, and what phases does it follow?

Phase 1: penetration and distribution build

• Initial years typically emphasize:
  • Securing chain placements
  • Building “repeat trial” through promotions
  • Expanding online availability and bundled offerings

Expected financial signature

• Faster unit growth than margin growth early on, due to trade spend and retailer onboarding.
• Higher marketing-to-sales ratio relative to mature stages.

Phase 2: normalization

• After distribution is broad:
  • The unit growth rate slows to category pace
  • Promotional intensity declines if the brand retains consumer loyalty
  • Gross margin improves if mix shifts to higher-retail channels

Phase 3: maturity with competitive pressure

• With time, market dynamics typically shift toward:
  • Price competition from generics or alternative OTC actives
  • Private label pressure in mainstream channels

Expected financial signature

• Revenue growth tracks:
  • Retail velocity (units)
  • Average selling price (pricing power)
  • Mix between retail and direct-to-consumer, when applicable

---

What patent and exclusivity situation affects LUMIFY competition risk and margin durability?

Patent-led vs non-patent-led competition

• Ophthalmic products with a branded OTC strategy often face:
  • Direct generic substitution when there is no strong remaining IP barrier
  • Formulation, concentration, or manufacturing method variants
  • Competing mechanisms that reduce brand pricing power even if brimonidine equivalents are limited

What drives the “effective exclusivity” window

• Regulatory exclusivity (if any for the NDA/505(b)(2) pathway)
  • Determines how easily generics can enter.
• Orange Book listing scope
  • Broad listing coverage can delay “authorized” substitutes and Paragraph IV litigation.
• Shelf economics
  • Even absent immediate legal entry, competitors can still out-market or undercut pricing in OTC retail.

Financial implication

• When legal exclusivity compresses, margin risk accelerates first in:
  • High-velocity retail chains
  • Channels where switching friction is low

---

Are generics or biosimilars relevant to LUMIFY’s competitive landscape?

Generics

• LUMIFY is a small-molecule ophthalmic product, so the relevant risk is generic small-molecule competition, not biosimilars.

What “generic entry” means in OTC eye drops

Generic entry typically hits via:

• Lower price equivalents at the pharmacy counter
• Increased promotional activity by entrants
• Private label substitution where retailers negotiate formulations and supply

Financial impact pattern

• Unit growth can slow immediately, followed by:
  • Brand share decline
  • Net sales softness if price cannot hold
  • Trade spend increases to defend shelf presence

---

What litigation or Paragraph IV dynamics could affect LUMIFY’s sales trajectory?

Typical pathways

For ophthalmic small molecules, litigation risks generally include:

• Paragraph IV challenges to patent listings in the Orange Book
• Settlement agreements that define a “carve-out” launch date
• Injunction leverage that can delay first generic shipments

How litigation would map to financial trajectory

• Before settlement/decision: uncertainty can push entrants to wait, supporting brand pricing.
• After settlement/decision: one-time competitive shock tends to occur at launch, then stabilizes with ongoing promo competition.

---

What is the FDA and Orange Book status of LUMIFY, and how does it affect market timing?

FDA status categories that matter commercially

• NDA vs 505(b)(2) vs ANDA structures affect:
  • Regulatory timelines for generics
  • Eligibility for exclusivities and listed patents
• Orange Book listings control:
  • When ANDA applicants can file
  • Whether Paragraph IV is required
  • Whether a 30-month stay triggers delay

Commercial translation

• A brand’s financial trajectory typically tracks the time-to-entry set by:
  • Last listed patent expiration
  • Any regulatory exclusivity end date
  • Settlement-imposed launch windows

---

How does LUMIFY compare with competing OTC redness relief drops in pricing power and switching risk?

Competitive set dynamics

LUMIFY competes in the same aisle as:

• Other redness relief actives
• Allergy-season variants with overlapping use-cases
• Vasoconstrictor and alternative-ingredient drops

What determines share shift

• Onset and duration perception
• Ease of use
• Stated “target redness” differentiation
• Value propositions
  • multi-pack pricing
  • subscription deals, if offered through direct channels
• Tolerability profile
  • sting sensitivity drives churn to another active

Financial implication

Even if legal substitution is delayed, brand pricing power is constrained by:

• Consumer experimentation in OTC
• Retailers’ private label and promo strategies

---

Which channel economics most influence LUMIFY revenue and EBITDA profile?

Retail pharmacy vs online

• Retail:
  • Higher dependence on chain-level relationships and merchandising
  • More immediate exposure to price matching
• Online:
  • Higher sensitivity to search rankings, reviews, and bundle offers
  • Promotions can increase unit volume but compress ASP

Trade spend and gross margin

• LUMIFY’s EBITDA leverage is driven by:
  • Net pricing after allowances
  • Manufacturing scale and inventory turns
  • Promotional cadence versus competitor discounting

---

What generic entry risks exist for LUMIFY by geography and timeline?

Geographic risk

• In the US, the risk is driven by:
  • Orange Book patent expiration and exclusivity
  • ANDA filing schedules
  • Litigation outcomes
• Outside the US, entry timing typically lags unless:
  • The molecule is already marketed through local equivalents
  • Regulatory pathway is efficient and patents are weak or expired

Timeline risk pattern

• Pre-launch “watchlist” effect
  • If investors or trade know a launch is imminent, brand pricing can soften earlier.
• Launch shock
  • Sales usually experience the sharpest decline at the first sustained availability of low-priced alternatives.
• Post-launch stabilization
  • Volume drops stabilize once channel managers decide on shelf allocation.

---

Key Takeaways

• LUMIFY’s financial trajectory is primarily a function of OTC category velocity, channel execution, and pricing power rather than chronic-disease scale.
• The main commercial threats are generic and mechanism competition that erodes brand share and forces higher trade spend.
• “Effective exclusivity” is driven by Orange Book-listed patents and any regulatory exclusivity, but even delayed legal entry can be undermined by substitutable OTC alternatives.
• EBITDA direction hinges on whether management can defend net price and protect distribution during the competitive transition.

---

FAQs

1) Does LUMIFY have biosimilar competition risk?

No. LUMIFY is a small-molecule ophthalmic drug; the relevant competition is generic substitution and other OTC redness relief actives, not biosimilars.

2) What most impacts LUMIFY net sales: units or average selling price?

Both matter, but unit velocity and retailer net pricing after allowances usually determine direction because OTC eye redness relief is highly substitutable.

3) How does Orange Book status translate into when generics can launch LUMIFY?

Orange Book patent listings and any applicable regulatory exclusivity set the legal entry timing for ANDAs and can trigger Paragraph IV-related stays or settlement-driven launch windows.

4) What is the likely pattern of brand revenue after the first generic launches?

A rapid share-and-price compression phase typically hits at initial availability, followed by partial stabilization as channels settle on shelf allocation.

5) Which competitive mechanism is the biggest threat to LUMIFY in retail?

Competitors that deliver comparable or faster perceived relief with lower price and strong retailer promotions tend to drive the highest switching risk in OTC redness relief.

---

References (APA)

1. FDA Orange Book. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drug Approval and Databases: Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. FDA. (n.d.). OTC Drug Facts and labeling resources. U.S. Food and Drug Administration. https://www.fda.gov/drugs/

DrugChatter Q&A for LUMIFY

When does lumify patent expiration date?
When can gen ereic andas be submitted for lumify side?
When doe steh lumify patent expire?
How much does lumify cost?
Is lumify preservative free?